Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Silence Therapeutics plcNASDAQ: SLN

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $14.96M (cash outflow) fell 32.3% year over year. Sequentially, it fell 81.8% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.

Context

  • Net income amounted to 15851.9% of revenue in FY2025, up 15785.0 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$25.57M (-71.1%) for the fiscal year ending Dec 2026, a slowdown from the +206.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.96M-81.8% QoQ
Last fiscal yearDec 2025
-$88.61M+206.4% YoY
LTMMar 2026
-$145.44M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.3%-75.5%-43.2 pp
1 year+206.4%-71.1%-277.6 pp
3-year CAGR+20.7%-29.8%-50.6 pp
5-year CAGR-22.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

Mixed currencies · from the cash flow

Latest · FY2025
(88.61M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Net income amounts to 15782.6% of revenue for SLN, versus a peer median of 173.5%.
SLN Competitors
Net Income for SLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$717.13M USD-2481.4%+50.8%159.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$546.15M USD+113.1%+12.2%56.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$183.59M USD+63.4%+8.1%255.7%
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M USD+15.4%—173.5%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.06M USD+126.2%+0.5%3.0%
RNAAtrium Therapeutics, Inc.FY2025$49.5M USD——265.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
BNTCBenitec Biopharma Inc.LTM Mar 2026$41.54M USD+56.8%+27.7%—
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding SLN) —+56.8%+10.2%173.5%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Net Income(61.89M)(50.33M)(50.31M)(28.92M)(88.61M)
Depreciation & Amortization576.29K596K498K473.86K555K
Deferred Income Tax5.95M688K0675.23K11K
Stock-Based Compensation11.65M12.69M13.05M10.41M8.07M
Change in Working Capital52.43M(19.4M)(11.66M)(26.39M)10.16M
Accounts Receivables37.09M(10.54M)314K(722.38K)5.07M
Inventory00000
Accounts Payables00000
Other Working Capital15.33M(8.85M)(11.98M)(25.67M)5.09M
Other Non-Cash Items468.32K(1.28M)9.07M(10.3M)7.54M
Operating Cash Flow9.19M(57.04M)(39.35M)(54.05M)(62.27M)
Capital Expenditures(1.8M)(545K)(45K)(168.61K)(55K)
Acquisitions (Net)00000
Purchases of Investments0(19.95M)(20.67M)(111.21M)(166.41M)
Sales of Investments13.5M036.18M0118.48M
Other Investing Activities(17.55K)(372K)958K93.82M0
Investing Cash Flow11.71M(20.5M)16.43M(17.55M)(47.99M)
Debt Repayment(284.77K)0(174K)00
Common Stock Issued41.73M52.58M25.33M113.54M15K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow41.45M52.58M25.16M113.54M15K
Effect of Forex Changes(141.71K)(8.12M)(3.02M)47.95K195K
Net Change in Cash62.2M(33.08M)(785K)41.98M(110.05M)
Free Cash Flow7.39M(57.59M)(39.4M)(54.22M)(62.33M)

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.